Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remdesivir in Hospitalized Children with RSV
NCT06873633Phase 2Recruiting
- Sponsor
- Penta Foundation
- Start
- Jul 2025
- Primary completion
- Jun 2026
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in respiratory syncytial virus infection (RSV) comparing Standard of Care with Remdesivir + SOC (2 arms). Primary endpoint: Safety and tolerability of Remdesivir at 1 week. Started Jul 2025; status: recruiting.
02
Drugs
remdesivir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06873633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06873633.